While intravitreal anti-vascular endothelial growth factor (VEGF) therapy effectively inhibits VEGF and is commonly used to treat diabetic macular edema and PDVR, some patients exhibit only a moderate or poor response to this approach [100]. The gene discussed is VEGFA; the disease is diabetic macular edema.